Sucampo Puts 40 Reps Behind Rescula Launch As it Seeks Revitalization
This article was originally published in The Pink Sheet Daily
Executive Summary
Tiny Sucampo is betting that its new drug Rescula can make inroads in a heavily generic market because of its clean safety profile and efficacy, but at $99 per 30-day supply WAC, it faces significant headwinds.
You may also be interested in...
Sucampo Re-Embraces Amitiza Through Co-Promote Option After Rescula Falters
While the company had been hopeful about diversifying its revenue base with the launch of its glaucoma drug Rescula, those hopes have faltered and pushed Sucampo to try to maximize the potential behind its main sales-driver, the constipation treatment Amitiza.
Merck’s New Glaucoma Drug Zioptan Faces Formidable Market Challenge
U.S. approval of the prostaglandin analogue adds to Merck’s ophthalmology portfolio, but it remains to be seen whether being preservative free confers tafluprost an advantage in a field that includes generics of the blockbuster Pfizer drug Xalatan.
IPO Update: Patheon Public Once Again, Audentes To Move Into The Clinic
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.